Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study

被引:24
|
作者
Hughes, Michael [1 ,2 ]
Zanatta, Elisabetta [3 ]
Sandler, Robert D. [4 ]
Avouac, Jerome [5 ]
Allanore, Yannick [5 ]
机构
[1] Tameside & Glossop Integrated Care NHS Fdn Trust, Dept Rheumatol, Fountain St, Ashton Under Lyne OL6 9RW, England
[2] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England
[3] Padova Univ Hosp, Dept Med DIMED, Div Rheumatol, Padua, Italy
[4] Royal Hallamshire Hosp, Sheffield Teaching Hosp Fdn Trust, Dept Rheumatol, Sheffield, S Yorkshire, England
[5] Ctr Univ Paris, Hop Cochin, AP HP, Serv Rhumatol, Paris, France
关键词
SSc; scleroderma; mortality; digital ulcers; pulmonary artery hypertension; scleroderma renal crisis; meta-analysis; systematic review; vasculopathy; PULMONARY ARTERIAL-HYPERTENSION; SCLERODERMA RENAL CRISIS; ISCHEMIC DIGITAL ULCERS; RAYNAUDS-PHENOMENON; IMPROVED SURVIVAL; RISK-FACTORS; DISEASE; PREVALENCE; MORTALITY; PREDICTORS;
D O I
10.1093/rheumatology/keab850
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Vascular disease in SSc is associated with significant morbidity and mortality. Preliminary data may lead to the suggestion of a modifiable unified-vascular endophenotype. Our aim was to determine whether the prevalence, mortality and severity of SSc-vascular disease have changed over time. Methods We performed a systematic review and meta-analysis of the literature in PubMed 1950-2019 related to SSc-digital ulcers (DUs), pulmonary artery hypertension (PAH) and scleroderma renal crisis (SRC). We included full-text articles and extracted study characteristics and assessed risk of bias/quality. We examined the prevalence, mortality and surrogate measures of SSc-associated vascular disease severity. Results We included 55 studies in our meta-analysis. The pooled prevalence of DUs (41.0%), PAH (9.5%) and SRC (4.9%) remained largely stable over time. There was significant improvement in PAH 1-year (P = 0.001) and SRC mortality (P < 0.001), but not PAH 3-year (P = 0.312) or 5-year (P = 0.686) mortality. The prevalence of DU healing did not significantly change (P = 0.265). There was a trend (all P = similar to 0.1) towards improvement in PAH surrogates: mean pulmonary artery pressure, pulmonary vascular resistance and right atrial pressure. For SRC, there was evidence that the overall frequency of dialysis (66.7%, P = 0.297) and permanent dialysis (35.4%, P = 0.036) increased over time. Conclusion Despite the heterogeneity and scarcity of the disease, there have been major improvements obtained in the various vascular complications in SSc leading to benefit in survival. This is supported by a trend towards improvement in several surrogate markers and demonstrates that progress in vascular management translates into major patient benefit.
引用
收藏
页码:2755 / 2769
页数:15
相关论文
共 50 条
  • [1] Atherosclerosis in Systemic Sclerosis A Systematic Review and Meta-Analysis
    Au, Karen
    Singh, Manjit K.
    Bodukam, Vijay
    Bae, Sangmee
    Maranian, Paul
    Ogawa, Rikke
    Spiege, Brennan
    McMahon, Maureen
    Hahn, Bevra
    Khanna, Dinesh
    ARTHRITIS AND RHEUMATISM, 2011, 63 (07): : 2078 - 2090
  • [2] Isoprostane in systemic sclerosis: A systematic review and meta-analysis
    Ames, Paul R. J.
    Merashli, Mira
    Bucci, Tommaso
    Nourooz-Zadeh, Jaffar
    MODERN RHEUMATOLOGY, 2019, 29 (03) : 470 - 475
  • [3] Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis
    Marina Maria Vieira de Figueiredo Caldas
    Kesley Pablo Morais de Azevedo
    Ana Clara de França Nunes
    Victor Hugo de Oliveira
    Isac Davidson Santiago Fernandes Pimenta
    Isabela Dantas Torres de Araújo
    Francisco Alves Bezerra Neto
    Ana Katherine da Silveira Gonçalves de Oliveira
    Grasiela Piuvezam
    Advances in Rheumatology, 61
  • [4] Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis
    Zhong, Lixian
    Pope, Melinda
    Shen, Ye
    Hernandez, Jose J.
    Wu, Lin
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (12) : 2096 - 2107
  • [5] Audiovestibular symptoms in systemic sclerosis: a systematic review and meta-analysis
    Salvador, Craig D.
    Keith, Brian A.
    Ward, Celine
    Nguyen, Shaun A.
    Gordis, Tamar
    Chidarala, Shreya
    Brennan, Emily
    Rizk, Habib
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2025, 282 (03) : 1147 - 1157
  • [6] Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis
    Blagojevic, Jelena
    AlOdhaibi, Khitam Abdullah
    Aly, Aly M.
    Matucci-Cerinic, Marco
    Furst, Daniel E.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [7] Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis
    de Figueiredo Caldas, Marina Maria Vieira
    de Azevedo, Kesley Pablo Morais
    de Franca Nunes, Ana Clara
    de Oliveira, Victor Hugo
    Pimenta, Isac Davidson Santiago Fernandes
    de Araujo, Isabela Dantas Torres
    Neto, Francisco Alves Bezerra
    da Silveira Goncalves de Oliveira, Ana Katherine
    Piuvezam, Grasiela
    ADVANCES IN RHEUMATOLOGY, 2021, 61 (01)
  • [8] Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
    Rubio-Rivas, Manuel
    Royo, Cristina
    Pilar Simeon, Carmen
    Corbella, Xavier
    Fonollosa, Vicent
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (02) : 208 - 219
  • [9] TOCILIZUMAB USE IN SYSTEMIC SCLEROSIS: SYSTEMATIC REVIEW AND META-ANALYSIS
    Dos-Santos, R.
    Guadalupe, E.
    Fernandez Fernandez, D.
    Gonzalez Fernandez, I.
    Sanchez-Wonenburger, M.
    Castro-Santamaria, P.
    Mata, A.
    Puga Guzman, J. L.
    Perez-Pampin, E.
    Souto Vilas, A.
    Mera Varela, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 101 - 102
  • [10] Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis
    Zinellu, Angelo
    Mangoni, Arduino A.
    FRONTIERS IN IMMUNOLOGY, 2024, 15